Purple Biotech LTD.: Form 20-F for the period ended Dec 31, 2021
Filed with the SEC on Mar 9, 2022 and accepted by EDGAR at Mar 9, 2022, 06:20 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Selling, general and administrative | 12 months2021-01-01 to 2021-12-31 | $6.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Net income | 12 months2021-01-01 to 2021-12-31 | $17.8m | us-gaap:ProfitLoss |
| Operating cash flow | 12 months2021-01-01 to 2021-12-31 | −$374.0k | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2021-01-01 to 2021-12-31 | $115.0k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2021-12-31 | $10.9m | ifrs-full:CashAndCashEquivalents |
| Total assets | At period end2021-12-31 | $70.2m | ifrs-full:Assets |
| Current liabilities | At period end2021-12-31 | $4.3m | ifrs-full:CurrentLiabilities |
| Shareholders' equity | At period end2021-12-31 | $64.8m | ifrs-full:EquityAttributableToOwnersOfParent |
| Shares outstanding | At period end2021-12-31 | 178,001,092 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001213900-22-011191. Last ingested by Listed: Nov 6, 2026, 18:16 ET. Listed shows no prices and gives no investment advice.